ArticleRegulatory toxicology and pharmacology : RTP2020
A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies.
Article in Regulatory toxicology and pharmacology : RTP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The OASIS Consortium: integrating multi-omics technologies to transform chemical safety assessment.Toxicological sciences : an official journal of the Society of Toxicology · 2025Article
- A new approach methodology to identify tumorigenic chemicals using short-term exposures and transcript profiling.Frontiers in toxicology · 2024Article
- Increased Cell Proliferation as a Key Event in Chemical Carcinogenesis: Application in an Integrated Approach for the Testing and Assessment of Non-Genotoxic Carcinogenesis.International journal of molecular sciences · 2023Review
- A tiered testing strategy based on in vitro phenotypic and transcriptomic data for selecting representative petroleum UVCBs for toxicity evaluation in vivo.Toxicological sciences : an official journal of the Society of Toxicology · 2023Article
- A Transformative Vision for an Omics-Based Regulatory Chemical Testing Paradigm.Toxicological sciences : an official journal of the Society of Toxicology · 2022Article
- Predicting Chemical Carcinogens Using a Hybrid Neural Network Deep Learning Method.Sensors (Basel, Switzerland) · 2022Article
- Review
- Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays.ALTEX · 2022Article
- Repeat-dose toxicity prediction with Generalized Read-Across (GenRA) using targeted transcriptomic data: A proof-of-concept case study.Computational toxicology (Amsterdam, Netherlands) · 2021Article
- DeepCarc: Deep Learning-Powered Carcinogenicity Prediction Using Model-Level Representation.Frontiers in artificial intelligence · 2021Article
- Quantification of cancer driver mutations in human breast and lung DNA using targeted, error-corrected CarcSeq.Environmental and molecular mutagenesis · 2020Article
- A Rat Liver Transcriptomic Point of Departure Predicts a Prospective Liver or Non-liver Apical Point of Departure.Toxicological sciences : an official journal of the Society of Toxicology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Robust genomic approaches are now available to realize improvements in efficiencies and translational relevance of cancer risk assessments for drugs and chemicals. Mechanistic and pathway data generated via genomics provide opportunities to advance beyond historical reliance on apical endpoints of uncertain human relevance. Published research and regulatory evaluations include many examples for which genomic data have been applied to address cancer risk assessment as a health protection endpoint. The alignment of mature, robust, reproducible, and affordable technologies with increasing demands for reduced animal testing sets the stage for this important transition. We present our shared vision for change from leading scientists from academic, government, nonprofit, and industrial sectors and chemical and pharmaceutical safety applications. This call to action builds upon a 2017 workshop on "Advances and Roadblocks for Use of Genomics in Cancer Risk Assessment." The authors propose a path for implementation of innovative cancer risk assessment including incorporating genomic signatures to assess mechanistic relevance of carcinogenicity and enhanced use of genomics in benchmark dose and point of departure evaluations. Novel opportunities for the chemical and pharmaceutical sectors to combine expertise, resources, and objectives to achieve a common goal of improved human health protection are identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.